bezlotoxumab sold brand name zinplava human monoclonal antibody designed prevention recurrence clostridioides difficile drug along actoxumab developed phase ii efficacy trials partnership medarex inc massbiologics university massachusetts medical project licensed merck sharp dohme corp development actoxumab bezlotoxumab fully human monoclonal antibodies bind c difficile toxins b respectivelycitation needed phase iii trial showed benefit bezlotoxumab combination actoxumab bezlotoxumab worked better prevent recurrence c difficile associated diarrhea bezlotoxumab june us fdas antimicrobial drugs advisory committee formerly known antiinfective drugs advisory met discuss bezlotoxumab committee voted recommend approval mercks license application vote generally expressing willingness accept trials proven bezlotoxumab decreased recurrence c difficile overall committee tempered acceptance robust discussion whether drug provide marked benefit patient groups expressed concern potential safety signal group treated bezlotoxumab data suggested bezlotoxumab might benefit sicker highrisk patients show statistical benefit patient subgroups although patient population whole contained many sick individuals thus many adverse events subjects receiving placebo receiving bezlotoxumab panel focused small number serious events patients preexisting congestive heart failure subset patients receiving bezlotoxumab appeared higher rate negative outcomes placebo group although may imbalance sick patients groups prescription drug user fee act pdufa action date fdas review bezlotoxumab july bezlotoxumab gained fda approval october indicated reduce recurrence clostridium difficile infection cdi patients years age older receiving antibiotics cdi high risk xray crystallized structure nterminal clostridioides difficile toxin b tcdb toxin identified consist three domains gtd cysteine protease combined repetitive oligopeptides crop domain crop domain consists four different peptide units bezlotoxumab specifically inhibits crop domain tcdb recognizes specific epitope toxin tcdb high affinity region gtd domain interact bezlotoxumab appears interact representative entire crop domain bezlotoxumab interacts either overlapping residues region two domains fragment interact specific portion crop domain characterization peptide full crop domain tcdb suggests antibody specifically reacts region crop domain leads conclusion tcdb epitope lies within nterminus crop httpsenwikipediaorgwikibezlotoxumab